tetano
Editor, Senior Moderator
J Immunol Methods
. 2023 Nov 29:113586.
doi: 10.1016/j.jim.2023.113586. Online ahead of print. Development of automated microfluidic immunoassays for the detection of SARS-CoV-2 antibodies and antigen
Linwood Johnson[SUP] 1 [/SUP], Maggie L Bartlett[SUP] 1 [/SUP], Francisco Ramirez[SUP] 2 [/SUP], Christopher D Heger[SUP] 2 [/SUP], Darci R Smith[SUP] 3 [/SUP]
Affiliations
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the coronavirus disease 2019 (COVID-19) global pandemic. Rapid and sensitive detection of the virus soon after infection is important for the treatment and prevention of transmission of COVID-19, and detection of antibodies is important for epidemiology, assessment of vaccine immunogenicity, and identification of the natural reservoir and intermediate host(s). Patient nasal or oropharyngeal swabs or saliva used in conjunction with polymerase chain reaction (PCR) detect SARS-CoV-2 RNA, whereas lateral flow immunoassays (LFI) detect SARS-CoV-2 proteins. Enzyme-linked immunosorbent assays (ELISA) detect anti-SARS-CoV-2 antibodies in blood. Although effective, these assays have poor sensitivity (e.g., LFI) or are labor intensive and time consuming (PCR and ELISA). Here we describe the development of rapid, automated ELISA-based immunoassays to detect SARS-CoV-2 antigens and antibodies against the virus. The Simple Plex™ platform uses rapid microfluidic reaction kinetics for sensitive analyte detection with small sample volumes. We developed three sensitive <90-min Simple Plex immunoassays that measure either the SARS-CoV-2 antigens or the immune response to SARS-CoV-2, including neutralizing antibodies, in serum from COVID-19 patients.
Keywords: Automated; COVID-19; Immunoassay; Microfluidic; SARS-CoV-2.
. 2023 Nov 29:113586.
doi: 10.1016/j.jim.2023.113586. Online ahead of print. Development of automated microfluidic immunoassays for the detection of SARS-CoV-2 antibodies and antigen
Linwood Johnson[SUP] 1 [/SUP], Maggie L Bartlett[SUP] 1 [/SUP], Francisco Ramirez[SUP] 2 [/SUP], Christopher D Heger[SUP] 2 [/SUP], Darci R Smith[SUP] 3 [/SUP]
Affiliations
- PMID: 38040191
- DOI: 10.1016/j.jim.2023.113586
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the coronavirus disease 2019 (COVID-19) global pandemic. Rapid and sensitive detection of the virus soon after infection is important for the treatment and prevention of transmission of COVID-19, and detection of antibodies is important for epidemiology, assessment of vaccine immunogenicity, and identification of the natural reservoir and intermediate host(s). Patient nasal or oropharyngeal swabs or saliva used in conjunction with polymerase chain reaction (PCR) detect SARS-CoV-2 RNA, whereas lateral flow immunoassays (LFI) detect SARS-CoV-2 proteins. Enzyme-linked immunosorbent assays (ELISA) detect anti-SARS-CoV-2 antibodies in blood. Although effective, these assays have poor sensitivity (e.g., LFI) or are labor intensive and time consuming (PCR and ELISA). Here we describe the development of rapid, automated ELISA-based immunoassays to detect SARS-CoV-2 antigens and antibodies against the virus. The Simple Plex™ platform uses rapid microfluidic reaction kinetics for sensitive analyte detection with small sample volumes. We developed three sensitive <90-min Simple Plex immunoassays that measure either the SARS-CoV-2 antigens or the immune response to SARS-CoV-2, including neutralizing antibodies, in serum from COVID-19 patients.
Keywords: Automated; COVID-19; Immunoassay; Microfluidic; SARS-CoV-2.